Exploring the Role of Antibody-Drug Conjugates in Cancer Care: A Foundational Program for Oncology Pharmacists

On May 4th, 2022 the FDA approved fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.

This activity includes animation videos and a Pocket Pharmacist guide*.

Program Description

New molecular entities continue to enter the treatment landscape for patients with hematologic malignancies and solid tumors. Though existing therapies have demonstrated efficacy, antibody-drug conjugates (ADCs) have been identified as having an improved therapeutic index and increased tumor selectivity. Pharmacists should be aware of the pharmacology and mechanisms of action of available and emerging ADCs in various malignancies. Indications for each of the ADCs currently FDA approved and others in the pipeline will be discussed throughout this program. A discussion of best practices for oncology pharmacists to manage adverse effects of therapy as well as drug management strategies for the preparation, dispensing, and administration of ADCs to optimize care of patients with cancer will be presented. This program will also feature video animations highlighting the unique chemical structures and mechanisms of action of FDA-approved ADCs.

Target audience: Health-system and oncology pharmacists

Type of activity: Application
Release date: July 1, 2022
Expiration date: July 1, 2023

Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Differentiate antibody-drug conjugates in oncology by unique mechanism of action and therapeutic target.
• Identify the role of antibody-drug conjugates in various cancer indications based on supportive clinical data and guideline recommendations.
• Examine the role of the pharmacist in optimizing the use of antibody-drug conjugates in various cancer indications.

*Refer to the Resources tab on the left pane in the activity to access the Pocket Pharmacist downloadable PDF. 

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-22-328-H01-P. The activity is available for CE credit through July 1, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Allison Schepers, PharmD, BCOP, has no financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Karleen Melody, PharmD; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta have no financial relationships with commercial interests to disclose.

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Brittany Hoffmann-Eubanks, PharmD, MBA, has no financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms